Loading
RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, animal model 0.65, genetic association 0.00, clinical 0.97).
In plain words · RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.
RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes.
No product in this corpus aims at RARB yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA RARB: RNA low tissue specificity; high antibody staining in 9 normal tissues; highest cancer staining pancreatic cancer (2 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute promyelocytic leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas RARB tissue; Open Targets ENSG00000077092 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Dejean et al, Nature, 1986, "Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma". Source.
Sources: HGNC HGNC:9865 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P10826 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000077092 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.60, myeloproliferative neoplasm 0.60, leukaemia 0.60, acute promyelocytic leukaemia 0.59 (GraphQL API, CC0))
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Location: Nucleus; Cytoplasm (UniProt). Locus 3p24.2 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adrenal gland, Breast, Bronchus, Cerebellum, Cervix, Colon, Epididymis, Fallopian tube.
Medium only: breast cancer, carcinoid, colorectal cancer, head and neck cancer.
HPA RARB tissue · HPA RARB pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RARB" OR ABSTRACT:"RARB" OR TITLE:"retinoic acid receptor beta" OR ABSTRACT:"retinoic acid receptor beta" OR TITLE:"Retinoic acid receptor beta" OR ABSTRACT:"Retinoic acid receptor beta" OR TITLE:"NR1B2" OR ABSTRACT:"NR1B2" OR TITLE:"RRB2" OR ABSTRACT:"RRB2" OR TITLE:"RARbeta" OR ABSTRACT:"RARbeta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RARB, not a curated reading list.
Shares Acute promyelocytic leukaemia, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.